




CALCBENCH


Next Generation Financial Data Tools

Biological Products Summary



Biological Products **Total Revenue** *up* by 60.2% in 3 years. **Revenue** *up* 45% YoY .¹

Top 3 Revenue Firms



1. numbers are reflective of the entire Calcbench reporting universe for the period. Over 5000 firms. Please note all data is based on Calendar Quarters, NOT Fiscal Quarters. Fiscal quarters provided upon request.




CALCBENCH

Next Generation Financial Data Tools


Biological Products Summary

Total Net Income




Biological Products Total Net Income up by 134% . Net Income up 97% YoY.¹

Total Operating Expenses



Biological Products Total Operating Expenses up by 28% . Operating Expenses up 17.3% YoY.¹

Total SG&A Expenses



Biological Products Total SG&A Expenses up by 20% . SG&A up 17% YoY.¹

1. numbers are reflective of the entire Calcbench reporting universe for the period. Over 5000 firms. Please note all data is based on Calendar Quarters, NOT Fiscal Quarters. Fiscal quarters provided upon request.




CALCBENCH

Next Generation Financial Data Tools


Biological Products Summary

Total Cash




Biological Products **Total Cash** down by 8% . **Cash up 97% YoY.**¹

Total Assets



Biological Products **Total Assets** up by 38% . **Assets up 18% YoY.**¹

Total Liabilities



Biological Products **Total Liabilities** up by 35.0% . **Liabilities up 14% YoY.**¹

1. numbers are reflective of the entire Calcbench reporting universe for the period. Over 5000 firms. Please note all data is based on Calendar Quarters, NOT Fiscal Quarters. Fiscal quarters provided upon request.




CALCBENCH

Next Generation Financial Data Tools


Biological Products Summary

Total Capex




Biological Products **Total Capex** up by 105% . **Capex** down 48% YoY.¹

Total R&D Expenses



Biological Products **Total R&D Expenses** up by 44% . **R&D** up 19% YoY.¹

Total Payments of Dividends



Biological Products **Total Payments of Dividends** up by 214% . **Payments of Dividends** up 21% YoY.¹

1. numbers are reflective of the entire Calcbench reporting universe for the period. Over 5000 firms. Please note all data is based on Calendar Quarters, NOT Fiscal Quarters. Fiscal quarters provided upon request.




CALCBENCH

Next Generation Financial Data Tools

Biological Products Summary

Days Sales Outstanding (DSO) can give a clearer picture of the landscape with respect to potential red flags regarding customer credit quality. See here DSO for End of Year 2014 and the median for the group of firms. *



*Outliers Winsorized at 95th Percentile.



6